Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: Results from two randomized studies

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Nunez, Derek J ^a   Bush, Mark A ^a,f   Collins, David A ^a   McMullen, Susan L ^a   Gillmor, Dawn ^a   Apseloff, Glen ^b   Atiee, George ^c   Corsino, Leonor ^d   Morrow, Linda ^e   Feldman, Paul L ^a  

^a GLAXOSMITHKLINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Worldwide Clinical Trials Drug Development Solutions   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Profil Institute for Clinical Research   (United States)

^f Nuventra Pharma Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [[[1 [3 (1 METHYLETHYL) 1,2,4 OXADIAZOL 5 YL] 4 PIPERIDINYL]METHYL]OXY] 2 [4 (METHYLSULFONYL)PHENYL]PYRIDINE; ANTIDIABETIC AGENT; C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GSK 1292263; GSK 263; INSULIN; METFORMIN; PEPTIDE YY; PLACEBO; SITAGLIPTIN; UNCLASSIFIED DRUG; (1-(3-ISOPROPYL-1,2,4-OXADIAZOL-5-YL)PIPERIDIN-4-YL)METHYL METHANESULFONATE; G PROTEIN COUPLED RECEPTOR; GASTROINTESTINAL HORMONE; GLUCOSE BLOOD LEVEL; GPR119 PROTEIN, HUMAN; MESYLIC ACID DERIVATIVE; OXADIAZOLE DERIVATIVE; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLURRED VISION; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; AGONISTS; ANALYSIS; BLOOD; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; METABOLISM; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

BLOOD GLUCOSE; C-PEPTIDE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL HORMONES; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MESYLATES; METFORMIN; MIDDLE AGED; OXADIAZOLES; PEPTIDE YY; PROGNOSIS; PYRAZINES; RECEPTORS, G-PROTEIN-COUPLED; TRIAZOLES;

EID: 84899061300     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092494     Document Type: Article

References (46)

1. Nauck MA (2009) Unraveling the science of incretin biology. Am J Med 122: S3-S10.
2. Drucker DJ (2006) The biology of incretin hormones. Cell Metab 3: 153-165.
3. Tharakan G, Tan T, Bloom S (2011) Emerging therapies in the treatment of 'diabesity': beyond GLP-1. Trends Pharmacol Sci 32: 8-15.
4. Deacon CF (2004) Circulation and degradation of GIP and GLP-1. Horm Metab Res 36: 761-765.
5. le Roux CW, Batterham RL, Aylwin SJ, Patterson M, Borg CM, et al. (2006) Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147: 3-8. (Pubitemid 43004254)
6. Deacon CF (2007) Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Expert Opin Investig Drugs 16: 533-545.
7. Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, et al. (2004) Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab 17: 336-342.
8. Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, et al. (2002) Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 298: 779-784. (Pubitemid 35356808)
9. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, et al. (2006) Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91: 4612-4619. (Pubitemid 44833446)
10. Correia S, Carvalho C, Santos MS, Seica R, Oliveira CR, et al. (2008) Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. Mini Rev Med Chem 8: 1343-1354.
11. Natali A, Ferrannini E (2006) Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 49: 434-441. (Pubitemid 43277865)
12. Odori S, Hosoda K, Tomita T, Fujikura J, Kusakabe T, et al. (2013) GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function. Metabolism 62: 70-78.
13. Ohishi T, Yoshida S (2012) The therapeutic potential of GPR119 agonists for type 2 diabetes. Expert Opin Investig Drugs 21: 321-328.
14. Katz LB, Gambale JJ, Rothenberg PL, Vanapalli SR, Vaccaro N, et al. (2011) Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects. Clin Pharmacol Ther 90: 685-692.
15. Fang J, Tang J, Carpenter AJ, Peckham G, Conlee CR, et al. (2008) Preparation of piperidine derivatives as GPR119 agonists for treating metabolic disorders. United States patent PCT/US2007/086434
16. Shah U, Kowalski TJ (2010) GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders. Vitam Horm 84:415-448.
17. International Conference on Harmonisation (1996) ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice. Version 10.
18. World Medical Association (2000) Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 284: 3043-3045.
19. Polli JW, Hussey E, Bush M, Generaux G, Smith G, et al. (2013) Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. Xenobiotica 43: 498-508.
20. Dalla MC, Campioni M, Polonsky KS, Basu R, Rizza RA, et al. (2005) Two-hour seven-sample oral glucose tolerance test and meal protocol: minimal model assessment of beta-cell responsivity and insulin sensitivity in nondiabetic individuals. Diabetes 54: 3265-3273. (Pubitemid 43334384)
21. Karra E, Chandarana K, Batterham RL (2009) The role of peptide YY in appetite regulation and obesity. J Physiol 587: 19-25.
22. Aaboe K, Knop FK, Vilsboll T, Deacon CF, Holst JJ, et al. (2010) Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab 12: 323-333.
23. Batterham RL, Cohen MA, Ellis SM, le Roux CW, Withers DJ, et al. (2003) Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349: 941-948. (Pubitemid 37064767)
24. Babilon S, Morl K, Beck-Sickinger AG (2013) Towards improved receptor targeting: anterograde transport, internalization and postendocytic trafficking of neuropeptide Y receptors. Biol Chem 394: 921-936.
25. Beckman LM, Beckman TR, Earthman CP (2010) Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review. J Am Diet Assoc 110: 571-584.
26. le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, et al. (2006) Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243: 108-114. (Pubitemid 43054062)
27. le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, et al. (2007) Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246: 780-785. (Pubitemid 350035654)
28. Chronaiou A, Tsoli M, Kehagias I, Leotsinidis M, Kalfarentzos F, et al. (2012) Lower Ghrelin Levels and Exaggerated Postprandial Peptide-YY, Glucagon-Like Peptide-1, and Insulin Responses, After Gastric Fundus Resection, in Patients Undergoing Roux-en-Y Gastric Bypass: A Randomized Clinical Trial. Obes Surg 22: 1761-70.
29. Engelstoft MS, Egerod KL, Lund ML, Schwartz TW (2013) Enteroendocrine cell types revisited. Curr Opin Pharmacol 13: 912-921.
30. Engelstoft MS, Egerod KL, Holst B, Schwartz TW (2008) A gut feeling for obesity: 7TM sensors on enteroendocrine cells. Cell Metab 8: 447-449.
31. Lan H, Vassileva G, Corona A, Liu L, Baker H, et al. (2009) GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. J Endocrinol 201: 219-230.
32. Migoya EM, Bergeron R, Miller JL, Snyder RN, Tanen M, et al. (2010) Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 88: 801-808.
33. Hinke SA, Kuhn-Wache K, Hoffmann T, Pederson RA, McIntosh CH, et al. (2002) Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 291: 1302-1308. (Pubitemid 34694333)
34. Cuthbertson J, Patterson S, O'Harte FP, Bell PM (2009) Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes. Diabet Med 26: 649-654.
35. Green BD, Irwin N, Duffy NA, Gault VA, O'Harte FP, et al. (2006) Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 547: 192-199. (Pubitemid 44373906)
36. Lindsay JR, Duffy NA, McKillop AM, Ardill J, O'Harte FP, et al. (2005) Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med 22: 654-657. (Pubitemid 40593146)
37. Thondam SK, Cross A, Cuthbertson DJ, Wilding JP, Daousi C (2012) Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus. Diabet Med 29: e205-e210.
38. El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, et al. (2007) The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab 92: 4165-4171. (Pubitemid 350074727)
39. Sze L, Purtell L, Jenkins A, Loughnan G, Smith E, et al. (2011) Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J Clin Endocrinol Metab 96: E1314-E1319.
40. Naslund E, Bogefors J, Skogar S, Gryback P, Jacobsson H, et al. (1999) GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 277: R910-R916. (Pubitemid 29458166)
41. Mulherin AJ, Oh AH, Kim H, Grieco A, Lauffer LM, et al. (2011) Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 152: 4610-4619.
42. Sangle GV, Lauffer LM, Grieco A, Trivedi S, Iakoubov R, et al. (2012) Novel Biological Action of the Dipeptidylpeptidase-IV Inhibitor, Sitagliptin, as a Glucagon-Like Peptide-1 Secretagogue. Endocrinology 153: 564-573.
43. Katz LB, Gambale JJ, Rothenberg PL, Vanapalli SR, Vaccaro N, et al. (2012) Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes Obes Metab 14: 709-716.
44. Roberts B, Gregoire FM, Karpf DB, Clemens E, Lavan B, et al. (2009) MBX-2982, a novel oral GPR119 agonist for the treatment of Type 2 Diabetes: Results of single and multiple dose studies. Diabetes 58: A43.
45. Roberts B, Karpf DB, Martin R, Lavan B, Wilson M, et al. (2010) MBX-2982, a novel GPR119 agonist, shows greater efficacy in patients with the most glucose intolerance: Results of a Phase 1 study with an improved formulation. Diabetes 59: 603-P.
46. Goodman ML, Dow J, van Vliet AA, Hadi S, Karbiche D, et al. (2011) The novel GPR119-recepor agonist PSN821 shows glucose lowering and decreased energy intake in patients with T2DM after 14 days treatment. Diabetes 60: A84.